PMID- 35743820
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Electronic)
IS  - 2075-1729 (Linking)
VI  - 12
IP  - 6
DP  - 2022 May 26
TI  - Monocyte Chemotactic Protein-1 (MCP1) Accumulation in Human Osteoclast Precursor 
      Cultures.
LID - 10.3390/life12060789 [doi]
LID - 789
AB  - In vitro osteoclast methods require constant treatment with macrophage colony 
      stimulating factor (M-CSF) to support precursor survival and addition of the 
      differentiation agent receptor activator of NF-kappaB ligand (RANKL). Constant 
      exposure to granulocyte macrophage colony stimulating factor (GM-CSF) suppresses 
      human osteoclast formation in vitro. Addition of the chemokine monocyte 
      chemotactic protein-1 (MCP1) to such cultures dramatically increases osteoclast 
      formation and overcomes GM-CSF mediated suppression. We investigated the effect 
      of M-CSF, GM-CSF and the combination of M-CSF and GM-CSF treatment on the 
      expression of chemokines in human CD14+ cells in culture. Of assayed chemokines, 
      MCP1 was the most abundant in terms of mRNA transcript and protein in M-CSF 
      treated cultures and was suppressed by GM-CSF. MCP1 protein accumulated up to 50 
      ng/mL in culture medium, greatly exceeding other assayed chemokines. C-C 
      chemokine receptor-2 (CCR2) is the receptor for MCP1: the formation of 
      osteoclast-like cells was inhibited by constant exposure to the CCR2 antagonist 
      RS102895, in part by decreasing expression of RANK, the receptor for RANKL.
FAU - Morrison, Nigel A
AU  - Morrison NA
AD  - School of Medical Science, Griffith University, Gold Coast Campus, Gold Coast, 
      QLD 4215, Australia.
FAU - Forwood, Mark R
AU  - Forwood MR
AD  - School of Medical Science, Griffith University, Gold Coast Campus, Gold Coast, 
      QLD 4215, Australia.
LA  - eng
GR  - grant 481946/National Health and Medical Research Council of Australia/
GR  - grant 481928/Queensland Cancer Fund/
PT  - Journal Article
DEP - 20220526
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC9224710
OTO - NOTNLM
OT  - granulocyte macrophage colony stimulating factor (GM-CSF)
OT  - human CD14+ mononuclear cells
OT  - macrophage colony stimulating factor (M-CSF)
OT  - monocyte chemotactic protein 1 (MCP-1)
OT  - osteoclast
OT  - receptor activator of NF-kappaB ligand (RANKL)
COIS- The authors declare no conflict of interest.
EDAT- 2022/06/25 06:00
MHDA- 2022/06/25 06:01
PMCR- 2022/05/26
CRDT- 2022/06/24 01:26
PHST- 2022/03/17 00:00 [received]
PHST- 2022/05/17 00:00 [revised]
PHST- 2022/05/23 00:00 [accepted]
PHST- 2022/06/24 01:26 [entrez]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/06/25 06:01 [medline]
PHST- 2022/05/26 00:00 [pmc-release]
AID - life12060789 [pii]
AID - life-12-00789 [pii]
AID - 10.3390/life12060789 [doi]
PST - epublish
SO  - Life (Basel). 2022 May 26;12(6):789. doi: 10.3390/life12060789.